# Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Study · id `cardio:ct-nct03242642` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03242642](<https://clinicaltrials.gov/study/NCT03242642>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03242642

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1056 participants.

## Technical summary

Registry record NCT03242642. Non-randomized; no masking; primary purpose treatment. Start 2017-10-23 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1056 participants (planned count; ClinicalTrials.gov record NCT03242642, source copy `cardio:ctgov-nct03242642-2026-10-30`, retrieved 2026-10-31)
- Started: 2017-10-23 (actual) (ClinicalTrials.gov record NCT03242642, source copy `cardio:ctgov-nct03242642-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT03242642, source copy `cardio:ctgov-nct03242642-2026-10-30`, retrieved 2026-10-31)
- Completion: 2036-07-07 (anticipated) (ClinicalTrials.gov record NCT03242642, source copy `cardio:ctgov-nct03242642-2026-10-30`, retrieved 2026-10-31)
- Countries: United States; Canada; Denmark (ClinicalTrials.gov record NCT03242642, source copy `cardio:ctgov-nct03242642-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03242642-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- Acronym: APOLLO
- Condition: Mitral Valve Regurgitation
- Intervention (Device): Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
- Intervention (Device): Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
- Lead sponsor: Medtronic Cardiovascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: d012d623ba10b683ae7dc657b2e1892dfcd225b8f7651ebf6d1b0f378e4590d1
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
